Antares Pharma, Inc.
Antares Pharma, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States. Founded in 1978, the company has established itself as a pioneer in the development of innovative drug delivery systems, particularly in the areas of injectable pharmaceuticals. With a focus on enhancing patient compliance and improving therapeutic outcomes, Antares Pharma offers a range of unique products, including its proprietary auto-injector technology and transdermal delivery systems. The company has achieved significant milestones, including partnerships with major pharmaceutical firms and the successful launch of several key products. Antares Pharma's commitment to innovation and quality has positioned it as a trusted name in the market, making substantial contributions to the fields of endocrinology, pain management, and other therapeutic areas.
DitchCarbon Score
How does Antares Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Antares Pharma, Inc.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Antares Pharma, Inc.'s reported carbon emissions
Antares Pharma, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Halozyme Therapeutics, Inc., which may influence its climate commitments and reporting practices. While Antares Pharma has not set specific reduction targets or initiatives, it is important to note that emissions data and climate strategies may be inherited from its parent company. As such, any climate commitments or performance metrics would need to be assessed in the context of Halozyme Therapeutics, Inc.'s sustainability efforts. In the absence of direct emissions data, stakeholders are encouraged to monitor Antares Pharma's future disclosures for any developments in their climate commitments or emissions reduction strategies.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Antares Pharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
